Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53

Experimental Cell Research

Volumn 271, Issue 2, 2001, Pages 305-314

  Bush, Jason A ^a   Cheung Jr , K John J ^a   Li, Gang ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apoptosis; Curcumin; Fas; Melanoma; p53

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CURCUMIN; FAS ANTIGEN; FAS RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CAPPING PHENOMENON; CELL AGGREGATION; CELL DEATH; CELL MEMBRANE; CELL SURVIVAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; MELANOMA CELL; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE;

EID: 0035842333     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2001.5381     Document Type: Article

References (53)

1. Cutaneous melanoma
2. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century
3. Apoptosis: Molecular mechanisms and implications for cancer chemotherapy
4. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice
5. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
6. Chemotherapy-induced apoptosis in melanoma cells is p53-dependent
7. p53-dependent apoptosis in melanoma cells after treatment with camptothecin
8. Curcumin as an inhibitor of cancer
9. Inhibitory effects of curcumin on tumorigenesis in mice
10. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties
11. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer
12. Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in JB6 cells and in mouse epidermis
13. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogenesis in Swiss mice
14. Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis
15. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines
16. Inhibition of the c-Jun terminal kinase (JNK) signaling pathway by curcumin
17. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin
18. Activation of transcription factor NF-kappaB is suppressed by curcumin (diferuloyl-methane)
19. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells
20. Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells
21. (-2) ion and cellular p53 protein by curcumin in colorectal carcinoma cells
22. Stimulation of the stress-induced expression of stress proteins by curcumin in cultured cells and in rat tissues in vivo
23. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis
24. p53 mutation in metastatic melanomas and primary melanomas from sun-exposed and sun-protected sites
25. An abnormality in the p53 pathway following γ-irradiation in many wild-type p53 human melanoma lines
26. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas
27. New colorimetric cytotoxicity assay for anticancer-drug screening
28. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates
29. A novel apoptosis-like pathway, independent of mitochondria and caspases, induced by curcumin in human lymphoblastoid T (Jurkat) cells
30. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells
31. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappaB, and p53
32. Curcumin blocks cytokine-mediated NF-kappaB activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappaB kinase activity
33. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis
34. Nuclear factor-kappaB and caspases co-operatively regulate the activation and apoptosis of human macrophages
35. Activation of NF-kappaB by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1
36. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis
37. Antitumor activity of curcumin is mediated through the induction of apoptosis in AK-5 tumor cells
38. Death receptors: Signaling and modulation
39. Nuclear and cell membrane effects contribute independently to the induction of apoptosis in human cells exposed to UVB radiation
40. Fas ligand-induced apoptosis
41. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines
42. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
43. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
44. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
45. Inhibition of caspase cascade by HTLV-I tax through induction of NF-kappaB nuclear translocation
46. Inhibition of death receptor signals by cellular FLIP
47. Induction of apoptosis by cancer chemotherapy
48. Death-effector filaments: Novel cytoplasmic structures that recruit caspases and trigger apoptosis
49. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs
50. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells
51. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L